Table 1.
Clinical trials for evaluating preventive and therapeutic options against SARS-CoV-2 (up to March 29th 2020).
| Clinical trials | Identifier | Status | country |
|---|---|---|---|
| Tocilizumab in COVID-19 Pneumonia | NCT04317092 | Recruiting | Italy |
| Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | NCT04315298 | Recruiting | United States |
| A Pilot Study of Sildenafil in COVID-19 | NCT04304313 | Recruiting | China |
| ACE Inhibitors, Angiotensin II Type-I Receptor Blockers, and Severity of COVID-19 (CODIV-ACE) | NCT04318418 | Not yet recruiting | Italy |
| Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19) | NCT04304053 | Recruiting | Spain |
| The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2 | NCT04313023 | Not yet recruiting | |
| The Use of Angiotensin-Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective? | NCT04322786 | Not yet recruiting | |
| Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. | NCT04290871 | Withdrawn | |
| Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19 | NCT04322396 | Not yet recruiting | |
| Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool | NCT04274322 | Not yet recruiting | |
| Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI | NCT04324073 | Not yet recruiting | France |
| Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study | NCT04325893 | Not yet recruiting | |
| Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients | NCT04293887 | Not yet recruiting | |
| Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia | NCT04275388 | Not yet recruiting | |
| Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2 | NCT04323527 | Recruiting | Brazil |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection | NCT04283461 | Recruiting | United States |
| Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | NCT04322682 | Recruiting | Canada |
| Tocilizumab for SARS-CoV2 Severe Pneumonitis | NCT04315480 | Not yet recruiting | Italy |
| Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV | NCT04252274 | Recruiting | China |
| Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection | NCT04251871 | Recruiting | China |
| COVIDL1: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection | NCT04326426 | Not yet recruiting | |
| Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | NCT04306393 | Recruiting | United States |
| Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections | NCT03331445 | Active, not recruiting | Canada |
| NK Cells Treatment for Novel Coronavirus Pneumonia | NCT04280224 | Recruiting | China |
| Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection | NCT04261907 | Not yet recruiting | |
| A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia | NCT04276987 | Not yet recruiting | |
| Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 | NCT04308668 | Recruiting | United States |
| STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects | NCT03808922 | Recruiting | United States |
| Norwegian Coronavirus Disease 2019 Study | NCT04316377 | Not yet recruiting | |
| Lessening Organ Dysfunction With VITamin C | NCT03680274 | Recruiting | Canada |
| Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure | NCT04244591 | Recruiting | China |
| Convalescent Plasma to Limit Coronavirus Associated Complications | NCT04325672 | Not yet recruiting | United States |
| Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia | NCT04264533 | Recruiting | China |
| Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure Drug: RoActemra iv, RoActemra sc, Kevzara sc | NCT04322773 | Not yet recruiting | Denmark |
| Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus | NCT04322123 | Not yet recruiting | Brazil |
| Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) | NCT04307693 | Recruiting | Korea |
| Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | NCT04292899 | Recruiting | United States |
| NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE) | NCT04315987 | Not yet recruiting | |
| Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT (BEST-RCT) | NCT04305106 | Recruiting | China |
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia | NCT04273529 | Not yet recruiting | |
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 | NCT04273581 | Not yet recruiting | |
| Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells | NCT04313322 | Recruiting | Jordan |
| Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA) | NCT04315896 | Not yet recruiting | |
| Tetrandrine Tablets Used in the Treatment of COVID-19 (TT-NPC) | NCT04308317 | Enrolling by invitation | China |
| Fingolimod in COVID-19 | NCT04280588 | Recruiting | China |
| CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (SAC-COVID)v | NCT04317040 | Not yet recruiting | United States |
| Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19) | NCT04288102 | Recruiting | China |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 | NCT04286503 | Not yet recruiting | |
| Efficacy and Safety of Corticosteroids in COVID-19(Methylprednisolone) | NCT04273321 | Recruiting | China |
| Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) | NCT04318444 | Not yet recruiting | United States |
| Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA) | NCT04318015 | Not yet recruiting | |
| Safety and Immunity of Covid-19 aAPC Vaccine | NCT04299724 | Recruiting | China |
| Immunity and Safety of Covid-19 Synthetic Minigene Vaccine | NCT04276896 | Recruiting | China |
| A Phase I Clinical Trial in 18–60 Adults (APICTH)(vaccine) | NCT04313127 | Recruiting | China |
| Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 | NCT04310228 | Recruiting | China |
| Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells | NCT04302519 | Not yet recruiting | |
| Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe) | NCT04295551 | Not yet recruiting | |
| Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV) | NCT04303507 | Not yet recruiting | |
| Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19) | NCT04273763 | Enrolling by invitation | China |
| Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19 | NCT04278963 | Active, not recruiting | China |
| Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquine for Treatment of COVID19: A Randomized Control Trial (THDMS-COVID19) | NCT04303299 | Not yet recruiting | Thailand |
| The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19 | NCT04285190 | Not yet recruiting | |
| Immunoregulatory Therapy for 2019-nCoV: PD-1 blocking antibody + standard treatment, Thymosin + standard treatment, standard treatment | NCT04268537 | Not yet recruiting | |
| Tocilizumab vs. CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 (TACOS) | NCT04306705 | Recruiting | China |
| Mild/Moderate 2019-nCoV Remdesivir RCT | NCT04252664 | Recruiting | China |
| Losartan for Patients With COVID-19 Requiring Hospitalization | NCT04312009 | Not yet recruiting | United States |
| Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy) Drug: Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Standard of care |
NCT04315948 | Not yet recruiting | |
| Losartan for Patients With COVID-19 Not Requiring Hospitalization | NCT04311177 | Not yet recruiting | United States |
| Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia | NCT04273646 | Not yet recruiting | China |
| Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus | NCT04252118 | Recruiting | China |
| The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia | NCT04261426 | Not yet recruiting | |
| A Prospective/Retrospective, Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia Drug: Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir |
NCT04255017 | recruiting | China |
| A Prospective/Retrospective, Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia Drug: Abidol hydrochloride, Abidol Hydrochloride combined with Interferon atomization |
NCT04254874 | recruiting | China |
| Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP) | NCT04275414 | recruiting | China |
| A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia | NCT04261270 | recruiting | China |
| Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress (COVID-AIV) | NCT04311697 | Not yet recruiting | Israel |
| The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia Drug: Methylprednisolone |
NCT04263402 | recruiting | China |
| Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 (NoCovid) | NCT04305457 | Recruiting | United States |
| Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) | NCT04320277 | Recruiting | Italy |
| Adaptive COVID-19 Treatment Trial (ACTT) Drug: Remdesivir |
NCT04280705 | Recruiting | United States |
| Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu Drug: N-acetylcysteine + Fuzheng Huayu Tablet, N-acetylcysteine + Placebo |
NCT04279197 | Recruiting | China |
| NO Prevention of COVID-19 for Healthcare Providers Drug: Inhaled nitric oxide gas |
NCT04312243 | Not yet recruiting | |
| Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients Drug: Immunoglobulin of cured patients, γ-Globulin |
NCT04264858 | Not yet recruiting | China |
| Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients Drug: Recombinant human interferon α1β |
NCT04293887 | Not yet recruiting | |
| Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff Drug: recombinant human Interferon Alpha-1b, thymosin alpha 1 |
NCT04320238 | Recruiting | China |
| Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 | NCT04292340 | Recruiting | China |
| Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus | NCT04260594 | Not yet recruiting | |
| Evaluation of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of Novel Coronavirus Infection Drug: Ganovo + ritonavir+/-Interferon nebulization |
NCT04291729 | Completed | China |
| Eculizumab (Soliris) in Covid-19 Infected Patients | NCT04288713 | Available | |
| Severe 2019-nCoV Remdesivir RCT | NCT04257656 | Recruiting | China |
| nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | NCT04306393 | Recruiting | United States |
| Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(CoV) Pneumonia | NCT04269525 | Recruiting | China |
| Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection | NCT04261907 | Not yet recruiting | |
| Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia | NCT04264533 | Recruiting | China |
| Expanded Access Remdesivir (RDV; GS-5734™) | NCT04302766 | Available | |
| Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia | NCT04275388 | Not yet recruiting | |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection | NCT04283461 | recruiting | United States |
| Tocilizumab for SARS-CoV2 Severe Pneumonitis | NCT04315480 | Not yet recruiting | Italy |
| Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV | NCT04252274 | recruiting | China |
| Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV) | NCT04261517 | Completed | China |
| Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules, Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) |
NCT04251871 | recruiting | China |
| Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia | NCT04275245 | recruiting | China |
| Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 | NCT04299152 | Not yet recruiting | |
| NK Cells Treatment for Novel Coronavirus Pneumonia | NCT04280224 | Recruiting | China |
| Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure Drug: methylprednisolone therapy |
NCT04244591 | Recruiting | China |
| Norwegian Coronavirus Disease 2019 Study Drug: Hydroxychloroquine Sulfate |
NCT04316377 | Not yet recruiting | |
| Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment | NCT04276688 | Recruiting | China |
| Post-exposure Prophylaxis for SARS-Coronavirus-2 Drug: Hydroxychloroquine | NCT04308668 | Recruiting | United States |
| A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia | NCT04276987 | Not yet recruiting | |
| Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection | NCT04290858 | Withdrawn | |
| Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19. | NCT04290871 | Withdrawn |